Our article, “Advanced extraction of urinary microRNA for early cancer detection,” was published on the 25th of October, 2021, in the online version of Nature, a weekly international journal publishing the finest peer-reviewed research in science and technology.
Recently, membrane-bound extracellular vesicles known as exosomes, which are released from cancer cells, have emerged as promising early cancer biomarkers. These contain microRNAs that can modulate gene expression in recipient cells in a tumour’s surrounding microenvironment, and they have been associated with the development and progression of the disease.
Craif is working on the development of a new liquid biopsy to distinguish between cancer patients and healthy individuals based on the expression pattern of microRNAs in urine.
Craif plans to launch its first urine liquid biopsy product in 2022, a cancer risk check testing service in the areas of ovarian cancer and lung cancer. In addition, Craif will provide this technology as a next-generation biomarker analysis service, and promote its vision of “realizing a society where people can live out their natural lives” through collaboration with various companies and academia, mainly in the medical and healthcare fields.
The article can be found at the following link.
※This article was sponsored by Craif, and edited by Nature.